A Phase I Multicenter Study of the Safety, Tolerability, Viral Shedding Profile, and Immunogenicity of a Recombinant, Live, Attenuated Respiratory Syncytial Virus Subgroup A Strain, rA2cp NS2 in Adults, RSV-Seropositive 15 to 59 Month Old Children, and RSV-Susceptible Children (Seronegative 6 to 24 Month Old Children and Unscreened 4 to 5 Month Old Children) (D133-P7) Wyeth Lederle Vaccines
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2006
At a glance
- Drugs Respiratory syncytial virus vaccine live (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 25 Nov 2005 New trial record.